Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGIV 10% in Mild to Moderate Alzheimer's Disease
NCT01524887Phase 3Terminated
- Sponsor
- Takeda
- Start
- Jan 2012
- Primary completion
- Jul 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
A Phase 3 trial of intravenous immunoglobulin G in Alzheimer's disease (AD), sponsored by Takeda. Started Jan 2012; status: terminated.
02
Drugs
intravenous immunoglobulin G
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01524887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01524887.